Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Condition(s):Breast CancerLast Updated:October 8, 2021Recruiting
Include Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:October 8, 2021Recruiting
Condition(s):Multiple MyelomaLast Updated:June 14, 2022Recruiting
Condition(s):Breast Neoplasms; Invasive Breast Cancer; Estrogen-receptor-positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 31, 2023Recruiting
Condition(s):Autism Spectrum DisorderLast Updated:December 8, 2022Not yet recruiting
Condition(s):Pain, Postoperative; Opioid UseLast Updated:July 21, 2022Recruiting
Condition(s):Chronic BronchitisLast Updated:June 14, 2022Recruiting
Condition(s):Preeclampsia Severe; Cardiovascular Diseases; Primary PreventionLast Updated:April 21, 2022Recruiting
Condition(s):Emergency General SurgeryLast Updated:December 13, 2021Recruiting
Condition(s):Long QT Syndrome; Abnormalities, Drug-InducedLast Updated:August 5, 2022Recruiting
Condition(s):Heart FailureLast Updated:March 28, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.